Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference11 articles.
1. Kidoguchi K, Kuniyoshi Y, Kataoka Y (2021) Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity? Submitted as Letter to the Editor to Annals of Hematology
2. Seydoux C, Medinger M, Gerull S, Halter J, Heim D, Chalandon Y, Levrat SM, Schanz U, Nair G, Ansari M, Simon P, Passweg JR, Cantoni N (2021) Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. Ann Hematol 100(1):209–216
3. Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25(9):915–924
4. Ramzi M, Namdari N, Haghighat S, Haghighinejad H (2020) Evaluation of reversed administration order of busulfan (BU) and cyclophosphamide (CY) as conditioning on liver toxicity in allogenic hematopoietic stem cell transplantation (ALL-HSCT). Int J Hematol Oncol Stem Cell Res 14(3):171–176
5. Richardson PG, Corbacioglu S (2020) Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J 10(3):29